Activating RAS mutations (mainly neuroblastoma ras viral oncogene homolog (NRAS) or v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS)) are detected in 32–50% of patients with MM [6]. Here, KRAS is linked to Miyoshi myopathy.